Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Monday, March 3rd.

Can-Fite BioPharma Trading Up 4.3 %

NYSE:CANF opened at $1.63 on Friday. The company has a market capitalization of $5.77 million, a P/E ratio of -0.91 and a beta of 1.12. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The business’s 50-day moving average is $1.59 and its 200 day moving average is $1.90.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.